Euclises Pharmaceuticals, Inc. Receives Notice of Patent Allowance from European Patent Office for New Class of Compounds for Treatment of Cancer, Pain and Inflammation

PRESS RELEASE: Euclises Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel COX-2 inhibitors for use in treating certain cancers, pain and inflammation, has received a Notice of Allowance from the European...